Business
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
Abivax shares added to recent gains after the French biotechnology company moved to bolster its balance sheet through an upsized stock offering, signaling investor appetite in the wake of positive clinical-trial data.
Paris-listed shares in Abivax were up 5% at 123.40 euros in European morning trading Thursday, which would be a new all-time high if sustained until market close, according to FactSet data. This gave the company a market value of roughly 10 billion euros ($11.26 billion) after a 46% rally this week.
Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
You must be logged in to post a comment Login